3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
12
INDUSTRY
6
NETWORK
1
Study Type
Interventional
1
Sponsor
Conditions
Leukemia, Myeloid, Acute
3
Breast Neoplasms
3
Prostatic Neoplasms
2
Neuroblastoma
2
Leukemia, Myelomonocytic, Acute
2
Leukemia, Monocytic, Acute
2
Leukemia, Megakaryoblastic, Acute
2
Leukemia, Erythroblastic, Acute
2
Leukemia
2
Endometrial Neoplasms
2
Congenital Abnormalities
2
Stage I Mixed Cell Type Kidney Wilms Tumor
1
Squamous Intraepithelial Lesions
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Pleuropulmonary blastoma
1
Papillomavirus Infections
1
Pain
1
Neurofibrosarcoma
1
Neoplasms
1
Myeloproliferative Syndrome, Transient
1
Meningioma
1
Melanoma
1
Malignant mesenchymal tumor
1
Lymphoma, Large B-Cell, Diffuse
1
Lung Neoplasms
1
Liposarcoma
1
Leukemia, Eosinophilic, Acute
1
Interventions
fludarabine phosphate
2
fludarabine
2
Whole-Body Irradiation
2
Tacrolimus
2
Surveys and Questionnaires
2
Proton Therapy
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Mycophenolic Acid
2
Music Therapy
2
Mesna
2
Melphalan
2
Interviews as Topic
2
Gene Expression Profiling
2
Cyclophosphamide
2
Busulfan
2
tremelimumab
1
motesanib diphosphate
1
luprolide acetate gel depot
1
liposomal amphotericin B
1
durvalumab
1
copanlisib
1
chlorhexidine gluconate
1
batifiban
1
Whole Genome Sequencing
1
Watchful Waiting
1
Thrombopoietin
1
Taxes
1
Spermine Synthase
1
Radiotherapy, Intensity-Modulated
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
NETWORK
×
Neoplasms
×
Observation
×
Clear all
NCT04442048
2025-12-30
COV-IMMUNO
Canadian Cancer Trials Group
Phase 3
Completed
195 enrolled